Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 15, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific shareholding changes and does not contain financial performance data.
Material Changes
The only material change disclosed is an increase in the shareholding of Director Mr. J D Coombe. On July 14, 2003, his interest increased by 109 Ordinary Shares at a price of £11.99 per share. This transaction resulted from the re-investment of the dividend paid to shareholders on July 3, 2003, under the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Director J D Coombe increased his shareholding by 109 shares on July 14, 2003.
- The transaction price was £11.99 per share.
- The purchase was funded by the re-investment of the dividend paid on July 3, 2003.
- This filing contains no financial performance data or strategic outlook.